Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice - PubMed

Affiliations

• PMID: 2124237

Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice

H F Starnes Jr et al. J Immunol. 1990.

Retraction in

• Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice.

  Starnes HF, Pearce M, Yim J, Abrams J, Tewari A, Zou J. Starnes HF, et al. J Immunol. 1992 Mar 15;148(6):1968. J Immunol. 1992. PMID: 1541834 No abstract available.

Abstract

Potentially fatal physiologic and metabolic derangements can occur in response to bacterial infection in animals and man. Recently it has been shown that alterations in the levels of circulating cytokines such as IL-6 and TNF-alpha occur shortly after bacterial challenge. To understand better the role of IL-6 in inflammation, we investigated the effects of in vivo anti-mouse IL-6 antibody treatment in a mouse model of septic shock. Rat anti-mouse IL-6 neutralizing mAb was produced from splenocytes of an animal immunized with mouse rIL-6. This mAb, MP5-20F3, was a very potent and specific antagonist of mouse IL-6 in vitro bioactivity, demonstrated using the NFS60 myelomonocytic and KD83 plasmacytoma target cell lines, and also immunoprecipitated radiolabeled IL-6. Anti-IL-6 mAb pretreatment of mice subsequently challenged with lethal doses of i.p. Escherichia coli or i.v. TNF-alpha protected mice from death caused by these treatments. Pretreatment of E. coli-challenged mice with anti-IL-6 led to an increase in serum TNF bioactivity, in comparison to isotype control antibody, implicating IL-6 as a negative modulator of TNF in vivo. Anti-TNF-alpha treatment of mice challenged i.p. with live E. coli resulted in a 70% decrease in serum IL-6 levels, determined by immunoenzymetric assay, compared to control antibody, thereby supporting a role for TNF-alpha as a positive regulator of IL-6 levels. We conclude that IL-6 is a mediator in lethal E. coli infection, and suggest that antagonists of IL-6 may be beneficial therapeutically in life-threatening bacterial infection.

Similar articles

• Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptor in various murine models.

  Libert C, Vink A, Coulie P, Brouckaert P, Everaerdt B, Van Snick J, Fiers W. Libert C, et al. Eur J Immunol. 1992 Oct;22(10):2625-30. doi: 10.1002/eji.1830221023. Eur J Immunol. 1992. PMID: 1327800

• Overexpression of interleukin-15 protects against Escherichia coli-induced shock accompanied by inhibition of tumor necrosis factor-alpha-induced apoptosis.

  Hiromatsu T, Yajima T, Matsuguchi T, Nishimura H, Wajjwalku W, Arai T, Nimura Y, Yoshikai Y. Hiromatsu T, et al. J Infect Dis. 2003 May 1;187(9):1442-51. doi: 10.1086/374643. Epub 2003 Apr 15. J Infect Dis. 2003. PMID: 12717626

• [Similarity and synergy of trauma and sepsis: role of tumor necrosis factor-alpha and interleukin-6].

  Tang GJ. Tang GJ. Acta Anaesthesiol Sin. 1996 Sep;34(3):141-9. Acta Anaesthesiol Sin. 1996. PMID: 9084538 Review. Chinese.

• Tumor necrosis factor in metabolism of disease: hormonal actions versus local tissue effects.

  Tracey KJ, Cerami A. Tracey KJ, et al. Nouv Rev Fr Hematol (1978). 1992;34 Suppl:S37-42. Nouv Rev Fr Hematol (1978). 1992. PMID: 1340527 Review.

Cited by

• Role of interleukin 6 (IL-6) in protection from lethal irradiation and in endocrine responses to IL-1 and tumor necrosis factor.

  Neta R, Perlstein R, Vogel SN, Ledney GD, Abrams J. Neta R, et al. J Exp Med. 1992 Mar 1;175(3):689-94. doi: 10.1084/jem.175.3.689. J Exp Med. 1992. PMID: 1311016 Free PMC article.

• Malaria mimicry with tumor necrosis factor. Contrasts between species of murine malaria and Plasmodium falciparum.

  Clark IA, MacMicking JD, Gray KM, Rockett KA, Cowden WB. Clark IA, et al. Am J Pathol. 1992 Feb;140(2):325-36. Am J Pathol. 1992. PMID: 1739126 Free PMC article.

• Concentrations of interleukin 6 and tumour necrosis factor in serum and stools of children with Shigella dysenteriae 1 infection.

  de Silva DG, Mendis LN, Sheron N, Alexander GJ, Candy DC, Chart H, Rowe B. de Silva DG, et al. Gut. 1993 Feb;34(2):194-8. doi: 10.1136/gut.34.2.194. Gut. 1993. PMID: 8432472 Free PMC article.

• T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6.

  Mizuhara H, O'Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K, Satoh S, Niwa M, Senoh H, Fujiwara H. Mizuhara H, et al. J Exp Med. 1994 May 1;179(5):1529-37. doi: 10.1084/jem.179.5.1529. J Exp Med. 1994. PMID: 8163936 Free PMC article.

• In vivo effects of the antiglucocorticoid RU 486 on glucocorticoid and cytokine responses to Escherichia coli endotoxin.

  Hawes AS, Rock CS, Keogh CV, Lowry SF, Calvano SE. Hawes AS, et al. Infect Immun. 1992 Jul;60(7):2641-7. doi: 10.1128/iai.60.7.2641-2647.1992. Infect Immun. 1992. PMID: 1612734 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • SciCrunch